These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10493248)

  • 1. Strategic issues in the design and interpretation of studies on metabolic polymorphisms and cancer.
    Vineis P; Malats N
    IARC Sci Publ; 1999; (148):51-61. PubMed ID: 10493248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological studies on genetic polymorphism: study design issues and measures of occurrence and association.
    Boffetta P; Pearce N
    IARC Sci Publ; 1999; (148):97-108. PubMed ID: 10493252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and analysis issues in case-control studies addressing genetic susceptibility.
    Brennan P
    IARC Sci Publ; 1999; (148):123-32. PubMed ID: 10493254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic analysis of metabolic polymorphisms in molecular epidemiological studies: social and ethical implications.
    Hainaut P; Vähäkangas K
    IARC Sci Publ; 1999; (148):395-402. PubMed ID: 10493266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between detoxifying enzyme polymorphisms and susceptibility to cancer.
    Fryer AA; Jones PW
    IARC Sci Publ; 1999; (148):303-22. PubMed ID: 10493264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiologic studies: pitfalls in interpretation.
    Westhoff CL
    Dialogues Contracept; 1995; 4(5):5-6, 8. PubMed ID: 12288680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measures of genotype versus gene products: promise and pitfalls in cancer prevention.
    Ahsan H; Rundle AG
    Carcinogenesis; 2003 Sep; 24(9):1429-34. PubMed ID: 12819189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Individual susceptibility to occupational carcinogens: the evidence from biomonitoring and molecular epidemiology studies].
    Pavanello S; Clonfero E
    G Ital Med Lav Ergon; 2004; 26(4):311-21. PubMed ID: 15584438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design options for molecular epidemiology research within cohort studies.
    Rundle AG; Vineis P; Ahsan H
    Cancer Epidemiol Biomarkers Prev; 2005 Aug; 14(8):1899-907. PubMed ID: 16103435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inherent difficulties in epidemiological studies involving phenotyping.
    Benhamou S; Bouchardy C; Jacqz-Aigrain E
    IARC Sci Publ; 1999; (148):63-75. PubMed ID: 10493249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of studies of selected metabolic polymorphisms and cancer.
    d'Errico A; Malats N; Vineis P; Boffetta P
    IARC Sci Publ; 1999; (148):323-93. PubMed ID: 10493265
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of case-parents trio for epidemiological studies of association between genetic polymorphisms and complex diseases].
    Santos JL; Pérez F; Carrasco E; Albala C
    Rev Med Chil; 2002 Nov; 130(11):1307-15. PubMed ID: 12587516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study.
    Hung RJ; Brennan P; Canzian F; Szeszenia-Dabrowska N; Zaridze D; Lissowska J; Rudnai P; Fabianova E; Mates D; Foretova L; Janout V; Bencko V; Chabrier A; Borel S; Hall J; Boffetta P
    J Natl Cancer Inst; 2005 Apr; 97(8):567-76. PubMed ID: 15840879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic and biochemical issues in the molecular epidemiology of cancer.
    Snyder R; Hong JY
    IARC Sci Publ; 2004; (157):51-69. PubMed ID: 15055290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular epidemiology: a tool for understanding mechanisms of disease.
    Boffetta P
    Eur J Surg Suppl; 2002; (587):62-9. PubMed ID: 16144203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Researches on genetics and genetic epidemiology of common complex diseases: challenge and strategies].
    Gu DF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Apr; 28(2):115-8. PubMed ID: 16733887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A note on the estimation of relative risks of rare genetic susceptibility markers.
    Begg CB; Berwick M
    Cancer Epidemiol Biomarkers Prev; 1997 Feb; 6(2):99-103. PubMed ID: 9037560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic dissection methods: designs used for tests of gene-environment interaction.
    Liu X; Fallin MD; Kao WH
    Curr Opin Genet Dev; 2004 Jun; 14(3):241-5. PubMed ID: 15172665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues in the epidemiological analysis and interpretation of intermediate biomarkers.
    Rundle A; Schwartz S
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):491-6. PubMed ID: 12814992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of biomarkers to elucidate genetic susceptibility to cancer.
    Au WW; Salama SA
    Environ Mol Mutagen; 2005; 45(2-3):222-8. PubMed ID: 15690341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.